INTERVENTION 1:	Intervention	0
Pemetrexed 600mg/m2	Intervention	1
pemetrexed	CHEBI:63616	0-10
Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles	Intervention	2
pemetrexed	CHEBI:63616	0-10
x	LABO:0000148	7-8
x	LABO:0000148	50-51
x	LABO:0000148	117-118
cyclophosphamide	CHEBI:4026	61-77
INTERVENTION 2:	Intervention	3
Pemetrexed 1800mg/m2	Intervention	4
pemetrexed	CHEBI:63616	0-10
Pemetrexed: 1800 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles	Intervention	5
pemetrexed	CHEBI:63616	0-10
x	LABO:0000148	7-8
x	LABO:0000148	51-52
x	LABO:0000148	118-119
cyclophosphamide	CHEBI:4026	62-78
Inclusion Criteria: - You must be female and at least 18 years old. - You must have been diagnosed with breast cancer. - Your pre-study lab tests are within study requirements. - You must be willing to take folic acid and vitamin B12. Exclusion Criteria: - You are pregnant or breastfeeding. - You have another illness that your doctor thinks would make you unable to participate. - You are currently taking aspirin or aspirin-like medicine and are unable to stop for a few days during each cycle of therapy.	Eligibility	0
female	PATO:0000383	34-40
breast cancer	DOID:1612	104-117
folic acid	CHEBI:27470	207-217
vitamin b12	CHEBI:176843	222-233
Outcome Measurement:	Results	0
Best Tumor Response	Results	1
Tumor response was assessed using radiological imaging, which was repeated every 6 weeks prior to every other cycle. Confirmation of response was to occur no less than 4 weeks (28 days) after the first evidence of response.	Results	2
Time frame: baseline to measured progressive disease	Results	3
time	PATO:0000165	0-4
progressive	HP:0003676	33-44
disease	DOID:4,OGMS:0000031	45-52
Results 1:	Results	4
Arm/Group Title: Pemetrexed 600mg/m2	Results	5
pemetrexed	CHEBI:63616	17-27
Arm/Group Description: Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles	Results	6
pemetrexed	CHEBI:63616	23-33
x	LABO:0000148	30-31
x	LABO:0000148	73-74
x	LABO:0000148	140-141
cyclophosphamide	CHEBI:4026	84-100
Overall Number of Participants Analyzed: 42	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  Complete Response: 0	Results	9
Partial Response: 8	Results	10
Stable Disease: 18	Results	11
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 13	Results	12
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Unknown: 3	Results	13
Not Assessed: 0	Results	14
Results 2:	Results	15
Arm/Group Title: Pemetrexed 1800mg/m2	Results	16
pemetrexed	CHEBI:63616	17-27
Arm/Group Description: Pemetrexed: 1800 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles	Results	17
pemetrexed	CHEBI:63616	23-33
x	LABO:0000148	30-31
x	LABO:0000148	74-75
x	LABO:0000148	141-142
cyclophosphamide	CHEBI:4026	85-101
Overall Number of Participants Analyzed: 61	Results	18
Measure Type: Number	Results	19
Unit of Measure: participants  Complete Response: 0	Results	20
Partial Response: 20	Results	21
Stable Disease: 26	Results	22
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 8	Results	23
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Unknown: 5	Results	24
Not Assessed: 2	Results	25
Adverse Events 1:	Adverse Events	0
Total: 6	Adverse Events	1
Agranulocytosis 0/42 (0.00%)	Adverse Events	2
agranulocytosis	HP:0012234,DOID:12987	0-15
Anaemia 2/42 (4.76%)	Adverse Events	3
Febrile neutropenia 1/42 (2.38%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 0/42 (0.00%)	Adverse Events	5
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 1/42 (2.38%)	Adverse Events	6
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 1/42 (2.38%)	Adverse Events	7
thrombocytopenia	HP:0001873,DOID:1588	0-16
Cardio-respiratory arrest 0/42 (0.00%)	Adverse Events	8
Pericardial effusion 1/42 (2.38%)	Adverse Events	9
pericardial effusion	HP:0001698,DOID:118	0-20
Gastric ulcer haemorrhage 0/42 (0.00%)	Adverse Events	10
gastric ulcer	HP:0002592,DOID:10808	0-13
Melaena 0/42 (0.00%)	Adverse Events	11
Fatigue 1/42 (2.38%)	Adverse Events	12
fatigue	HP:0012378	0-7
Multi-organ failure 0/42 (0.00%)	Adverse Events	13
Adverse Events 2:	Adverse Events	14
Total: 13	Adverse Events	15
Agranulocytosis 1/61 (1.64%)	Adverse Events	16
agranulocytosis	HP:0012234,DOID:12987	0-15
Anaemia 1/61 (1.64%)	Adverse Events	17
Febrile neutropenia 0/61 (0.00%)	Adverse Events	18
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 2/61 (3.28%)	Adverse Events	19
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 2/61 (3.28%)	Adverse Events	20
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 1/61 (1.64%)	Adverse Events	21
thrombocytopenia	HP:0001873,DOID:1588	0-16
Cardio-respiratory arrest 1/61 (1.64%)	Adverse Events	22
Pericardial effusion 0/61 (0.00%)	Adverse Events	23
pericardial effusion	HP:0001698,DOID:118	0-20
Gastric ulcer haemorrhage 1/61 (1.64%)	Adverse Events	24
gastric ulcer	HP:0002592,DOID:10808	0-13
Melaena 1/61 (1.64%)	Adverse Events	25
Fatigue 1/61 (1.64%)	Adverse Events	26
fatigue	HP:0012378	0-7
Multi-organ failure 1/61 (1.64%)	Adverse Events	27
